These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 3103408

  • 1. Parkinson's disease: current view.
    Langston JW.
    Am Fam Physician; 1987 Mar; 35(3):201-6. PubMed ID: 3103408
    [Abstract] [Full Text] [Related]

  • 2. Ro 16-6491: a new reversible and highly selective MAO-B inhibitor protects mice from the dopaminergic neurotoxicity of MPTP.
    Da Prada M, Kettler R, Keller HH, Bonetti EP, Imhof R.
    Adv Neurol; 1987 Mar; 45():175-8. PubMed ID: 2881442
    [No Abstract] [Full Text] [Related]

  • 3. Big first scored with nerve diseases.
    Lewin R.
    Science; 1989 Aug 04; 245(4917):467-8. PubMed ID: 2502841
    [No Abstract] [Full Text] [Related]

  • 4. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
    Jenner P, Marsden CD.
    J Neural Transm Suppl; 1986 Aug 04; 20():11-39. PubMed ID: 3091760
    [Abstract] [Full Text] [Related]

  • 5. (-)Deprenyl in perspective: prophylaxis for Parkinson's disease?
    Sandler M.
    J Neural Transm Suppl; 1986 Aug 04; 22():107-15. PubMed ID: 3097254
    [Abstract] [Full Text] [Related]

  • 6. MAO type B inhibitors as adjunct to L-dopa therapy.
    Youdim MB, Finberg JP.
    Adv Neurol; 1987 Aug 04; 45():127-36. PubMed ID: 3103383
    [No Abstract] [Full Text] [Related]

  • 7. R-(-)-deprenyl as a possible protective agent in Parkinson's disease.
    Tetrud JW, Langston JW.
    J Neural Transm Suppl; 1987 Aug 04; 25():69-79. PubMed ID: 3123606
    [Abstract] [Full Text] [Related]

  • 8. The role of MAO in MPTP toxicity--a review.
    Glover V, Gibb C, Sandler M.
    J Neural Transm Suppl; 1986 Aug 04; 20():65-76. PubMed ID: 3091762
    [Abstract] [Full Text] [Related]

  • 9. Clinical trial for Parkinson's disease?
    Lewin R.
    Science; 1985 Nov 01; 230(4725):527-8. PubMed ID: 3931220
    [No Abstract] [Full Text] [Related]

  • 10. MPTP: a pharmacological tool to study parkinsonism.
    Kulkarni SK, Mehta AK, Aley KO, Shukla VK.
    Methods Find Exp Clin Pharmacol; 1986 Aug 01; 8(8):485-9. PubMed ID: 3489146
    [Abstract] [Full Text] [Related]

  • 11. Selegiline and the prophylaxis of Parkinson's disease.
    Sandler M, Willoughby J, Glover V, Gibb C.
    J Neural Transm Suppl; 1987 Aug 01; 25():35-43. PubMed ID: 3123604
    [Abstract] [Full Text] [Related]

  • 12. Parkinson's disease.
    Lieberman AN.
    Compr Ther; 1986 Mar 01; 12(3):25-9. PubMed ID: 3486090
    [No Abstract] [Full Text] [Related]

  • 13. Evidence for neuromelanin involvement in MPTP-induced neurotoxicity.
    D'Amato RJ, Alexander GM, Schwartzman RJ, Kitt CA, Price DL, Snyder SH.
    Nature; 1986 Mar 01; 327(6120):324-6. PubMed ID: 2884568
    [Abstract] [Full Text] [Related]

  • 14. [Significance of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine for the etiology and therapy of idiopathic Parkinson disease].
    Lange KW.
    Fortschr Neurol Psychiatr; 1989 Apr 01; 57(4):142-8. PubMed ID: 2656447
    [Abstract] [Full Text] [Related]

  • 15. MPTP toxicity: implications for research in Parkinson's disease.
    Kopin IJ, Markey SP.
    Annu Rev Neurosci; 1988 Apr 01; 11():81-96. PubMed ID: 3129982
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.